Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sejal Kothadia"'
Autor:
Miguel Gonzalez Velez, Narjust Duma, Tariq U. Azam, Sejal Kothadia, Joleen M. Hubbard, Ronald S. Go, Thorvardur R. Halfdanarson, Alex A. Adjei, Siddhartha Yadav, Aaron S. Mansfield, Jonas Paludo, Jesus Vera Aguilera, Julian R. Molina
Publikováno v:
The Oncologist. 24:96-102
Background Early phase clinical trials evaluate the safety and efficacy of new treatments. The exclusion/inclusion criteria in these trials are usually rigorous and may exclude many patients seen in clinical practice. Our objective was to study the c
Autor:
Khalid Matin, Emma C. Fields, Andrew Poklepovic, Sejal Kothadia, Sarah W. Gordon, Maciej Kmieciak, Dipankar Bandyopadhyay, Bhaumik Patel, Jennifer Myers, William McGuire, Mary Beth Tombes, Paul Dent, Brian J. Kaplan
Publikováno v:
Journal of Clinical Oncology. 39:e16268-e16268
e16268 Background: The multi-kinase inhibitor sorafenib (S) and HDAC inhibitor vorinostat (V) demonstrated synergism against preclinincal pancreatic cancer (PaCa) models. The combination of S & V also potently radiosensitized pancreatic cancer cells
Publikováno v:
Journal of the American College of Cardiology. 73:500
The Bone Marrow Transplant Survivor Study indicates that two-thirds of hematopoietic stem cell transplantation (HSCT) survivors develop a chronic health condition. Arrhythmia has been identified as a complication of HSCT in single-institution reports
Autor:
David S. Siegel, Jieqi Liu, Giselle A. Suero-Abreu, Rima M Panchal, Noa Biran, David H. Vesole, Ricardo D. Parrondo, Sejal Kothadia, Tracy Andrews, Camille Johnson
Publikováno v:
Blood. 132:3254-3254
Introduction: In the ASPIRE and ENDEAVOR trials, multiple myeloma (MM) patients treated with carfilzomib (K) had significantly improved progression‐free survival and overall survival compared with standard of care. The incidence of all-grade advers
Autor:
Giselle A. Suero-Abreu, Ning Dong, Martin Gutierrez, Narjust Duma, Miguel Gonzalez Velez, Sejal Kothadia, Daniel Pievsky, Tracy Ann Proverbs-Singh, Shalini R. Krishnasamy, Umar Sharif Khawaja, Marshall McKenna, Janice Liu
Publikováno v:
Journal of Clinical Oncology. 36:93-93
93 Background: Tumor mutational load (TML) has been proposed as a biomarker of responsiveness to novel immune checkpoint inhibitors (ICIs) due its association with increased neoantigen formation and tumor immunogenicity. Gastrointestinal cancers (GIC
Autor:
Sejal Kothadia, David Klein, Stephanie Hwa, Victor T. Chang, Ellen Olson, Yeun-Hee Anna Park, Zhen Wang, Fengming Zhong, Andrea Leaf, Sarah Lee
Publikováno v:
Journal of Clinical Oncology. 35:e21621-e21621
e21621 Background: Palliative and end of life care is essential for lung cancer pts. We examined palliative care delivery for lung cancer pts at 2 VA medical centers. Methods: In an IRB approved protocol, we reviewed medical records of matched pts di
Autor:
Yucai Wang, Sejal Kothadia, Sarah Lee, Yeun-Hee Anna Park, Zhen Wang, Ellen Olson, Victor T. Chang, Fengming Zhong, Andrea Leaf, Stephanie Hwa, David Klein
Publikováno v:
Journal of Clinical Oncology. 35:e21642-e21642
e21642 Background: Little is known about palliative care for liver cancer. In this study, we examined palliative care for liver cancer and lung cancer patients. Methods: In an IRB approved protocol, we reviewed medical records of patients diagnosed w
Autor:
Sejal Kothadia, Andrew Jennis, Martin Gutierrez, Narjust Duma, Ricardo Daniel Parrondo, Veronica Mariotti, Valentina Jaramillo Restrepo, Beth Boseski, Pablo Lopez-Zertuche, Miguel Gonzalez Velez
Publikováno v:
Journal of Clinical Oncology. 35:803-803
803 Background: The routine use of comprehensive genomic profiling (CGP) has led to better genomic characterization, more personalized treatments and higher enrollment in clinical trials for many solid cancers. The aim of this study was to evaluate t
Autor:
Veronica Mariotti, Beth Boseski, Miguel Gonzalez Velez, Sejal Kothadia, Ricardo Daniel Parrondo, Valentina Jaramillo Restrepo, Martin Gutierrez, Narjust Duma, Pablo Lopez-Zertuche, Andrew Jennis
Publikováno v:
Journal of Clinical Oncology. 35:774-774
774 Background: The use of next-generation sequencing (NGS) in clinical practice has increased the therapeutic options for many cancers. Multiple NGS assays are now commercially used. The genomic libraries used by these assays are continuously being
Autor:
V. Jaramillo Restrepo, Beth Boseski, H. Harper, Marshall McKenna, Veronica Mariotti, Sejal Kothadia, Ricardo Daniel Parrondo, Martin Gutierrez, M. Gonzalez Velez, M. Palascak, Narjust Duma
Publikováno v:
European Journal of Cancer. 72:S186